ENVB earnings analysis
What we found in ENVB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Enveric’s diluted loss improved substantially to $0.76 per share from $11.65 year over year, but net loss increased to $3.0 million from $2.5 million. The company raised approximately $6.5 million and held $8.3 million in cash while continuing to advance EB-003 toward an IND and Phase 1 trial. Persistent losses, unresolved control weaknesses, financing needs, and potential Nasdaq compliance pressure keep the overall outlook mixed.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Diluted loss improved year over year
- Diluted loss improved to $0.76 per share in Q2 2026 from $11.65 per share in Q2 2025, although the company remained loss-making.
- Raised $6.5 million during the quarter
- The company raised approximately $6.5 million during the quarter and reported $8.3 million of cash, supporting near-term development activities.
- EB-003 advanced toward Phase 1
- Enveric continued advancing EB-003 toward an IND application and Phase 1 trial, maintaining its stated development plan.
- Control weaknesses remain unresolved
- Management concluded that disclosure controls were not effective as of June 30, 2026, reflecting previously identified material weaknesses in internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent operating losses
- The company reported a $3.0 million net loss for Q2 2026 versus a $2.5 million net loss in the prior-year quarter, indicating continued operating losses despite the improvement in per-share loss.
- Financing and cash-burn risk
- Reported cash was $8.3 million after raising approximately $6.5 million during the quarter, leaving ongoing dependence on additional financing to fund development and operations.
- Potential Nasdaq delisting risk
- Nasdaq’s approved continued-listing requirement generally requires market value of listed securities of at least $5 million. The company stated its MVLS had recently been near that threshold, creating potential delisting risk if the rule becomes operative.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.76
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management reiterated plans to complete IND-enabling activities, submit an IND application, and advance EB-003 into a Phase 1 trial.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Enveric Biosciences reported no revenue for Q4 2025, with a diluted EPS of -0.5, which is a significant improvement from previous periods; however, the company continues to face considerable losses. Operating expenses…
- 10-K · March 27, 2026
- Enveric remains a pre-revenue, R&D-stage biotech focused on its lead neuroplastogen EB-003 (EVM301 Series), which has completed short-term dose-range finding toxicology and is "ready to advance into IND-enabling, GLP…
- 10-Q · August 14, 2025
- Enveric reported no revenue and a Q2 2025 net loss of $2,519,181 (EPS $(0.97)) vs. a Q2 2024 net loss of $1,879,394 (EPS $(3.72)); operating expenses rose to $2,519,049 from $1,897,931 driven by R&D growth. Cash…
- 10-Q · May 15, 2024
- Enveric reported a narrower net loss of $(2,456,915) for the three months ended March 31, 2024 versus a net loss attributable to shareholders of $(4,800,847) in the prior year period, and EPS improved to $(0.61) from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ENVB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever